Daniela Correia Salles

Daniela Correia Salles

Auto-generated profile, based on publicly available information

Daniela Correia Salles

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2022 in The Journal of Pathology
Verified
Journal Article
Open access
PDF file
DSDaniela C. Salles
Daniela C. Salles
KAKaushal Asrani
Kaushal Asrani
JWJuhyung Woo
Juhyung Woo
TVThiago Vidotto
Thiago Vidotto
HLHans B. Liu
Hans B. Liu
TLTamara L. Lotan
Tamara L. Lotan
GPNMB (glycoprotein nonmetastatic B) and other TFE3/TFEB transcriptional targets have been proposed as markers for microphthalmia (MiT) translocation renal cell carcinomas (tRCCs). We recently demonstrated that constitutive mTORC1 activation via TSC1/2 loss leads to increased activity of TFE3/TFEB, suggesting that the pathogenesis and molecular markers for tRCCs and TSC1/2‐associated tumors may be overlapping. We examined GPNMB expression in human kidney and angiomyolipoma (AML) cell lines with TSC2 and/or TFE3/TFEB loss produced using CRISPR–Cas9 genome editing as well as in a mouse model of Tsc2 inactivation‐driven renal tumorigenesis. Using an automated immunohistochemistry (IHC) assay for GPNMB, digital image analysis was employed to quantitatively score expression in clear cell RCC (ccRCC, n = 87), papillary RCC (papRCC, n = 53), chromophobe RCC (chRCC, n = 34), oncocytoma (n = 4), TFE3‐ or TFEB‐driven tRCC (n = 56), eosinophilic solid and cystic RCC (ESC, n = 6), eosinophilic vacuolated tumor (EVT, n = 4), and low‐grade oncocytic tumor (LOT, n = 3), as well as AML (n = 29) and perivascular epithelioid cell tumors (PEComas, n = 8). In cell lines, GPNMB was upregulated following TSC2 loss in a MiT/TFE‐ and mTORC1‐dependent fashion. Renal tumors in Tsc2+/− A/J mice showed upregulation of GPNMB compared with normal kidney. Mean GPNMB expression was significantly higher in tRCC than in ccRCC (p < 0.0001), papRCC (p < 0.0001), and chRCC (p < 0.0001). GPNMB expression in TSC1/2/MTOR alteration‐associated renal tumors (including ESC, LOT, AML, and PEComa) was comparable to that in tRCC. The immunophenotype of tRCC and TSC1/2/MTOR alteration‐associated renal tumors is highly overlapping, likely due to the increased activity of TFE3/TFEB in both, revealing an important caveat regarding the use of TFE3/TFEB‐transcriptional targets as diagnostic markers. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

18 January 2021 in Laboratory Investigation
Verified
Journal Article
Closed access
TLTamara L. Lotan
Tamara L. Lotan
HKHarsimar B. Kaur
Harsimar B. Kaur
DSDaniela C. Salles
Daniela C. Salles
SMSanjana Murali
Sanjana Murali
ESEdward M. Schaeffer
Edward M. Schaeffer
Emmanuel S. AntonarakisEmmanuel S. Antonarakis
Emmanuel S. Antonarakis

10 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
AWAdam B. Weiner
Adam B. Weiner
TVThiago Vidotto
Thiago Vidotto
YLYang Liu
Yang Liu
AMAdrianna A. Mendes
Adrianna A. Mendes
DSDaniela C. Salles
Daniela C. Salles
ESEdward M. Schaeffer
Edward M. Schaeffer
Black men die more often of prostate cancer yet, interestingly, may derive greater survival benefits from immune-based treatment with sipuleucel-T. Since no signatures of immune-responsiveness exist for prostate cancer, we explored race-based immune-profiles to identify vulnerabilities. Here we show in multiple independent cohorts comprised of over 1,300 patient samples annotated with either self-identified race or genetic ancestry, prostate tumors from Black men or men of African ancestry have increases in plasma cell infiltrate and augmented markers of NK cell activity and IgG expression. These findings are associated with improved recurrence-free survival following surgery and nominate plasma cells as drivers of prostate cancer immune-responsiveness.

1 April 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
RLRebeca Lozano
Rebeca Lozano
DSDaniela C. Salles
Daniela C. Salles
SSShahneen Sandhu
Shahneen Sandhu
IAIsabel M. Aragón
Isabel M. Aragón
HTHeather Thorne
Heather Thorne
Elena CastroElena Castro
Elena Castro

21 July 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
HKHarsimar Kaur
Harsimar Kaur
DSDaniela C. Salles
Daniela C. Salles
SMSanjana Murali
Sanjana Murali
JHJessica L. Hicks
Jessica L. Hicks
MNMinh Nguyen
Minh Nguyen
TLTamara L. Lotan
Tamara L. Lotan
Purpose: The ATM (ataxia telangiectasia mutated) gene is mutated in a subset of prostate cancers, and ATM mutation may confer specific therapeutic vulnerabilities, although ATM-deficient prostate cancers have not been well-characterized.Experimental Design: We genetically validated a clinical grade IHC assay to detect ATM protein loss and examined the frequency of ATM loss among tumors with pathogenic germline ATM mutations and genetically unselected primary prostate carcinomas using tissue microarrays (TMAs). Immunostaining results were correlated with targeted somatic genomic sequencing and clinical outcomes.Results: ATM protein loss was found in 13% (7/52) of primary Gleason pattern 5 cancers with available sequencing data and was 100% sensitive for biallelic ATM inactivation. In a separate cohort with pathogenic germline ATM mutations, 74% (14/19) had ATM protein loss of which 70% (7/10) of evaluable cases had genomic evidence of biallelic inactivation, compared with zero of four of cases with intact ATM expression. By TMA screening, ATM loss was identified in 3% (25/831) of evaluable primary tumors, more commonly in grade group 5 (17/181; 9%) compared with all other grades (8/650; 1%; P < 0.0001). Of those with available sequencing, 80% (4/5) with homogeneous ATM protein loss and 50% (6/12) with heterogeneous ATM protein loss had detectable pathogenic ATM alterations. In surgically treated patients, ATM loss was not significantly associated with clinical outcomes in random-effects Cox models after adjusting for clinicopathologic variables.Conclusions: ATM loss is enriched among high-grade prostate cancers. Optimal evaluation of ATM status requires both genomic and IHC studies and will guide development of molecularly targeted therapies.

10 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
KAKaushal Asrani
Kaushal Asrani
JWJuhyung Woo
Juhyung Woo
AMAdrianna A. Mendes
Adrianna A. Mendes
ESEthan Schaffer
Ethan Schaffer
TVThiago Vidotto
Thiago Vidotto
TLTamara L. Lotan
Tamara L. Lotan
The mechanistic target of rapamycin complex 1 (mTORC1) integrates inputs from growth factors and nutrients, but how mTORC1 autoregulates its activity remains unclear. The MiT/TFE transcription factors are phosphorylated and inactivated by mTORC1 following lysosomal recruitment by RagC/D GTPases in response to amino acid stimulation. We find that starvation-induced lysosomal localization of the RagC/D GAP complex, FLCN:FNIP2, is markedly impaired in a mTORC1-sensitive manner in renal cells with TSC2 loss, resulting in unexpected TFEB hypophosphorylation and activation upon feeding. TFEB phosphorylation in TSC2-null renal cells is partially restored by destabilization of the lysosomal folliculin complex (LFC) induced by FLCN mutants and is fully rescued by forced lysosomal localization of the FLCN:FNIP2 dimer. Our data indicate that a negative feedback loop constrains amino acid-induced, FLCN:FNIP2-mediated RagC activity in renal cells with constitutive mTORC1 signaling, and the resulting MiT/TFE hyperactivation may drive oncogenesis with loss of the TSC2 tumor suppressor.